Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04223856
Title Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

transitional cell carcinoma

Therapies

Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Enfortumab vedotin-ejfv + Pembrolizumab

Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.